Medication Errors During Treatment with New Oral Anticancer Agents: Consequences for Clinical Practice Based on the AMBORA Study.

Clinical Pharmacology and Therapeutics
Katja SchlichtigMartin F Fromm

Abstract

Patients treated with oral anticancer agents (e.g., kinase inhibitors) are a high-risk population for medication errors due to, for example, polymedication, age, and limited adherence. Systematic evaluations regarding frequencies and causes of medication errors and resulting harm are lacking. Our previously published multicenter randomized AMBORA trial revealed that an intensified support by clinical pharmacologists/pharmacists for patients and the treatment team considerably reduced drug-related problems and improved patient-reported outcomes. Using this database, we performed a comprehensive, additional analysis focusing on medication errors related to the patients' complete medication with consideration of the antitumor agents, concomitantly administered drugs, and herb/food intake. Two hundred two patients starting a new oral anticancer drug regardless of the tumor entity were included. Clinical pharmacologists/pharmacists performed advanced medication reviews for 12 weeks. Medication errors were characterized regarding type, cause, patient harm, and the involved medicines. We detected 1.7 medication errors per patient (335/202). Of the medication errors (216/335), 64.5% occurred within the concomitant medication. Patients ...Continue Reading

References

Jul 1, 1979·British Journal of Clinical Pharmacology·D A LeeV H James
Oct 1, 1992·Journal of Clinical Epidemiology·J T HanlonJ R Feussner
Jan 1, 1997·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·G LiuE Warner
Aug 20, 2003·Clinical Oncology : a Journal of the Royal College of Radiologists·C ClippeV Trillet-Lenoir
Oct 26, 2005·Cancer·Tejal K GandhiDavid W Bates
Apr 19, 2007·Journal of the National Cancer Institute·Rachel P RiechelmannMonika K Krzyzanowska
May 1, 2007·American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists·Joseph Aisner
Dec 31, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Kathleen E WalshJerry H Gurwitz
Mar 13, 2010·Cancer·Saul N WeingartMaureen Connor
Apr 14, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·David MarinJamshid S Khorashad
Feb 16, 2013·British Journal of Cancer·R W F van LeeuwenF G A Jansman
Apr 17, 2013·Expert Opinion on Drug Safety·Esther CarceleroNatalia Creus
May 1, 2013·Pediatrics·Kathleen E WalshKathleen M Mazor
Apr 1, 2015·American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists·Barry GoldspielJharana Tina Patel
Dec 31, 2015·International Journal of Clinical Pharmacy·Almudena RibedMaria Sanjurjo-Sáez
Oct 14, 2016·JAMA Oncology·Sandeep Parsad, Mark J Ratain
Jun 2, 2017·JAMA Oncology·Jessica A ZerilloMonika K Krzyzanowska
Dec 3, 2017·Clinical Pharmacology in Drug Development·Jiexin DengLawrence J Lesko
Apr 4, 2018·The Lancet Oncology·Saul N WeingartMichael Hassett
Sep 2, 2018·Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners·Jenna M SolomonEric H Bernicker
Oct 17, 2018·European Journal of Cancer Care·Gisela Riu-ViladomsNatàlia Creus
Jan 30, 2019·Journal of the American Geriatrics Society·UNKNOWN By the 2019 American Geriatrics Society Beers Criteria® Update Expert Panel
Dec 6, 2019·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·Sung Hwan KimJu-Yeun Lee
Sep 1, 2012·Annals of Oncology : Official Journal of the European Society for Medical Oncology·C F XuL N Pandite
Jul 28, 2020·BMC Pharmacology & Toxicology·Dolores OchoaFrancisco Abad-Santos
Apr 7, 2021·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Pauline DürrMartin F Fromm

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.